CoChat

Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL)

Open access
Mocciaro, Gabriele, Allison, Michael, Jenkins, Benjamin, Azzu, Vian, Huang-Doran, Isabel, Herrera-Marcos, Luis Vicente, Hall, Zoe, Murgia, Antonio, Susan, Davies, Frontini, Mattia, Vidal-Puig, Antonio, Koulman, Albert, Griffin, Julian L., Vacca, Michele · 2023 · Molecular Metabolism
Cited by 56

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVES: Non-alcoholic fatty liver disease (NAFLD) develops due to impaired hepatic lipid fluxes and is a risk factor for chronic liver disease and atherosclerosis. Lipidomic studies consistently reported characteristic hepatic/VLDL "lipid signatures" in NAFLD; whole plasma traits are more debated. Surprisingly, the HDL lipid composition by mass spectrometry has not been characterised across the NAFLD spectrum, despite HDL being a possible source of hepatic lipids delivered from peripheral tissues alongside free fatty acids (FFA). This study characterises the HDL lipidomic signature in NAFLD, and its correlation with metabolic and liver disease markers. METHODS: We used liquid chromatography-mass spectrometry to determine the whole serum and HDL lipidomic profile in 89 biopsy-proven NAFLD patients and 20 sex and age-matched controls. RESULTS: In the whole serum of NAFLD versus controls, we report a depletion in polyunsaturated (PUFA) phospholipids (PL) and FFA; with PUFA PL being also lower in HDL, and negatively correlated with BMI, insulin resistance, triglycerides, and hepatocyte ballooning. In the HDL of the NAFLD group we also describe higher saturated ceramides, which positively correlate with insulin resistance and transaminases. CONCLUSION: NAFLD features lower serum lipid species containing polyunsaturated fatty acids; the most affected lipid fractions are FFA and (HDL) phospholipids; our data suggest a possible defect in the transfer of PUFA from peripheral tissues to the liver in NAFLD. Mechanistic studies are required to explore the biological implications of our findings addressing if HDL composition can influence liver metabolism and damage, thus contributing to NAFLD pathophysiology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molmet.2023.101728

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 62

  1. Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 · DOI · Paper page
  2. Targher, 2020, NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications, Gut, 69, 1691, 10.1136/gutjnl-2020-320622 · DOI · Paper page
  3. Guerra, 2022, Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis, Eur J Clin Invest, 52, 10.1111/eci.13695 · DOI
  4. Morigny, 2021, Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics, Nat Rev Endocrinol, 17, 276, 10.1038/s41574-021-00471-8 · DOI · Paper page
  5. Mocciaro, 2022, Obesity-related insulin resistance: the central role of adipose tissue dysfunction, Handb Exp Pharmacol, 274, 145, 10.1007/164_2021_573 · DOI
  6. Mayo, 2018, Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts, Hepatol Commun, 2, 807, 10.1002/hep4.1188 · DOI · Paper page
  7. Yang, 2017, Serum monounsaturated triacylglycerol predicts steatohepatitis in patients with non-alcoholic fatty liver disease and chronic hepatitis B, Sci Rep, 7
  8. Zhou, 2016, Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites, Clin Gastroenterol Hepatol, 14, 1463, 10.1016/j.cgh.2016.05.046 · DOI
  9. Donnelly, 2005, Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J Clin Invest, 115, 1343, 10.1172/JCI23621 · DOI · Paper page
  10. Capel, 2020, Metabolomics reveals plausible interactive effects between dairy product consumption and metabolic syndrome in humans, Clin Nutr, 39, 1497, 10.1016/j.clnu.2019.06.013 · DOI
  11. Seyres, 2022, Transcriptional, epigenetic and metabolic signatures in cardiometabolic syndrome defined by extreme phenotypes, Clin Epigenetics, 14, 39, 10.1186/s13148-022-01257-z · DOI
  12. Mocciaro, 2022, Lipidomic approaches to study HDL metabolism in patients with central obesity diagnosed with metabolic syndrome, Int J Mol Sci, 23, 10.3390/ijms23126786 · DOI
  13. Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
  14. Bedossa, 2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002/hep.25889 · DOI · Paper page
  15. Kotronen, 2009, Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors, Gastroenterology, 137, 865, 10.1053/j.gastro.2009.06.005 · DOI · Paper page
  16. Meikle, 2017, Sphingolipids and phospholipids in insulin resistance and related metabolic disorders, Nat Rev Endocrinol, 13, 79, 10.1038/nrendo.2016.169 · DOI · Paper page
  17. Beyene, 2020, Correction: high-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: evidence from two large population cohort studies, PLoS Biol, 18, 10.1371/journal.pbio.3001049 · DOI
  18. Bui, 2012, Analysis of sphingolipids in extracted human plasma using liquid chromatography electrospray ionization tandem mass spectrometry, Anal Biochem, 423, 187, 10.1016/j.ab.2012.01.027 · DOI
  19. Hammad, 2010, Blood sphingolipidomics in healthy humans: impact of sample collection methodology, J Lipid Res, 51, 3074, 10.1194/jlr.D008532 · DOI · Paper page
  20. Mielke, 2015, Demographic and clinical variables affecting mid- to late-life trajectories of plasma ceramide and dihydroceramide species, Aging Cell, 14, 1014, 10.1111/acel.12369 · DOI
  21. Vvedenskaya, 2021, Nonalcoholic fatty liver disease stratification by liver lipidomics, J Lipid Res, 62, 10.1016/j.jlr.2021.100104 · DOI
  22. Ferrara, 2021, Lysophospholipid acylation modulates plasma membrane lipid organization and insulin sensitivity in skeletal muscle, J Clin Invest, 131, 10.1172/JCI135963 · DOI
  23. Pietilainen, 2011, Association of lipidome remodeling in the adipocyte membrane with acquired obesity in humans, PLoS Biol, 9, 10.1371/journal.pbio.1000623 · DOI · Paper page
  24. Singaraja, 2006, Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo, Circulation, 114, 1301, 10.1161/CIRCULATIONAHA.106.621433 · DOI · Paper page
  25. Sano, 2007, Sphingomyelin-dependence of cholesterol efflux mediated by ABCG1, J Lipid Res, 48, 2377, 10.1194/jlr.M700139-JLR200 · DOI
  26. Camont, 2013, Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities, Arterioscler Thromb Vasc Biol, 33, 2715, 10.1161/ATVBAHA.113.301468 · DOI · Paper page
  27. van der Veen, 2012, The membrane lipid phosphatidylcholine is an unexpected source of triacylglycerol in the liver, J Biol Chem, 287, 23418, 10.1074/jbc.M112.381723 · DOI · Paper page
  28. Kartsoli, 2020, Lipidomics in non-alcoholic fatty liver disease, World J Hepatol, 12, 436, 10.4254/wjh.v12.i8.436 · DOI
  29. Oresic, 2013, Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids, Diabetologia, 56, 2266, 10.1007/s00125-013-2981-2 · DOI · Paper page
  30. Ding, 2020, A review of lipidomics of cardiovascular disease highlights the importance of isolating lipoproteins, Metabolites, 10, 10.3390/metabo10040163 · DOI
  31. Kontush, 2013, Unraveling the complexities of the HDL lipidome, J Lipid Res, 54, 2950, 10.1194/jlr.R036095 · DOI · Paper page
  32. Boon, 2013, Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance, Diabetes, 62, 401, 10.2337/db12-0686 · DOI · Paper page
  33. Carlier, 2020, Dihydroceramides in triglyceride-enriched VLDL are associated with nonalcoholic fatty liver disease severity in type 2 diabetes, Cell Rep Med, 1
  34. Bevilacqua, 1987, Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects, Metabolism, 36, 502, 10.1016/0026-0495(87)90051-5 · DOI · Paper page
  35. Lomonaco, 2012, Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease, Hepatology, 55, 1389, 10.1002/hep.25539 · DOI · Paper page
  36. Feng, 2017, Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case - control study, Lipids Health Dis, 16, 165, 10.1186/s12944-017-0551-1 · DOI · Paper page
  37. Ducheix, 2013, Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor, J Hepatol, 58, 984, 10.1016/j.jhep.2013.01.006 · DOI
  38. Neschen, 2007, n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner, Diabetes, 56, 1034, 10.2337/db06-1206 · DOI · Paper page
  39. Scorletti, 2018, Omega-3 fatty acids and non-alcoholic fatty liver disease: evidence of efficacy and mechanism of action, Mol Aspects Med, 64, 135, 10.1016/j.mam.2018.03.001 · DOI · Paper page
  40. Hodson, 2008, Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake, Prog Lipid Res, 47, 348, 10.1016/j.plipres.2008.03.003 · DOI · Paper page
  41. Leaf, 1995, Incorporation of dietary n-3 fatty acids into the fatty acids of human adipose tissue and plasma lipid classes, Am J Clin Nutr, 62, 68, 10.1093/ajcn/62.1.68 · DOI
  42. Jacobsen, 1983, Acyl pattern of adipose tissue triglycerides, plasma free fatty acids, and diet of a group of men participating in a primary coronary prevention program (the Oslo Study), Am J Clin Nutr, 38, 906, 10.1093/ajcn/38.6.906 · DOI
  43. Parry, 2021, Oxidation of dietary linoleate occurs to a greater extent than dietary palmitate in vivo in humans, Clin Nutr, 40, 1108, 10.1016/j.clnu.2020.07.013 · DOI
  44. Burke, 2009, Phospholipase A2 biochemistry, Cardiovasc Drugs Ther, 23, 49, 10.1007/s10557-008-6132-9 · DOI · Paper page
  45. Schwendeman, 2015, The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties, J Lipid Res, 56, 1727, 10.1194/jlr.M060285 · DOI · Paper page
  46. Hong, 2022, Effect of lipid composition on the atheroprotective properties of HDL-mimicking micelles, Pharmaceutics, 14, 10.3390/pharmaceutics14081570 · DOI
  47. McCullough, 2019, HDL flux is higher in patients with nonalcoholic fatty liver disease, Am J Physiol Endocrinol Metab, 317, E852, 10.1152/ajpendo.00193.2019 · DOI
  48. Di Costanzo, 2020, HDL-mediated cholesterol efflux and plasma loading capacities are altered in subjects with metabolically- but not genetically driven non-alcoholic fatty liver disease (NAFLD), Biomedicines, 8, 10.3390/biomedicines8120625 · DOI
  49. Fadaei, 2018, Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis, Sci Rep, 8, 10.1038/s41598-018-29639-5 · DOI · Paper page
  50. Zannis, 2015, HDL biogenesis, remodeling, and catabolism, Handb Exp Pharmacol, 224, 53, 10.1007/978-3-319-09665-0_2 · DOI · Paper page
  51. Robichaud, 2009, Hepatic uptake and metabolism of phosphatidylcholine associated with high density lipoproteins, Biochim Biophys Acta, 1790, 538, 10.1016/j.bbagen.2009.02.010 · DOI
  52. Borggreve, 2003, Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins, Eur J Clin Invest, 33, 1051, 10.1111/j.1365-2362.2003.01263.x · DOI · Paper page
  53. D'Amore, 2018, Identification of miR-9-5p as direct regulator of ABCA1 and HDL-driven reverse cholesterol transport in circulating CD14+ cells of patients with metabolic syndrome, Cardiovasc Res, 114, 1154, 10.1093/cvr/cvy077 · DOI
  54. Prada, 2021, Association of the odd-chain fatty acid content in lipid groups with type 2 diabetes risk: a targeted analysis of lipidomics data in the EPIC-Potsdam cohort, Clin Nutr, 40, 4988, 10.1016/j.clnu.2021.06.006 · DOI
  55. Imamura, 2017, A combination of plasma phospholipid fatty acids and its association with incidence of type 2 diabetes: the EPIC-InterAct case-cohort study, PLoS Med, 14, 10.1371/journal.pmed.1002409 · DOI
  56. Abdullah, 2015, Recommended dairy product intake modulates circulating fatty acid profile in healthy adults: a multi-centre cross-over study, Br J Nutr, 113, 435, 10.1017/S0007114514003894 · DOI
  57. Weitkunat, 2017, Odd-chain fatty acids as a biomarker for dietary fiber intake: a novel pathway for endogenous production from propionate, Am J Clin Nutr, 105, 1544, 10.3945/ajcn.117.152702 · DOI · Paper page
  58. Jenkins, 2017, Odd chain fatty acids; new insights of the relationship between the gut microbiota, dietary intake, biosynthesis and glucose intolerance, Sci Rep, 7, 10.1038/srep44845 · DOI
  59. Wallace, 2018, Enzyme promiscuity drives branched-chain fatty acid synthesis in adipose tissues, Nat Chem Biol, 14, 1021, 10.1038/s41589-018-0132-2 · DOI · Paper page
  60. Iqbal, 2015, Microsomal triglyceride transfer protein transfers and determines plasma concentrations of ceramide and sphingomyelin but not glycosylceramide, J Biol Chem, 290, 25863, 10.1074/jbc.M115.659110 · DOI
  61. Chaurasia, 2021, Ceramides in metabolism: key lipotoxic players, Annu Rev Physiol, 83, 303, 10.1146/annurev-physiol-031620-093815 · DOI · Paper page
  62. Patanapirunhakit, 2021, Sphingolipids in HDL - potential markers for adaptation to pregnancy?, Biochim Biophys Acta Mol Cell Biol Lipids, 1866

Cited by

See all 56

Metadata

Authors
Mocciaro, G., Allison, M., Jenkins, B., Azzu, V., Huang-Doran, I., Herrera-Marcos, L. V., Hall, Z., Murgia, A., Susan, D., Frontini, M., Vidal-Puig, A., Koulman, A., Griffin, J. L., & Vacca, M.
Venue
Molecular Metabolism
Publisher
Elsevier BV
Published
2023-07
Volume
73
Pages
101728
ISSN
2212-8778 (ISSN-L)
OpenAlex
W4366418525
Cited by
56
References
22
FWCI
9.37
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • UKRI Medical Research Council (MC PC 13030, MR/W019132/1, MC UP A90 1006)
  • Governo Italiano Ministero dell'Istruzione dell'Università e della Ricerca
  • NIHR Cambridge Biomedical Research Centre (IS-BRC-1215-20014)
  • Mason Medical Research Trust
  • University of Bari Aldo Moro
  • Foundation for Liver Research
  • National Institute for Health and Care Research
  • Evelyn Trust
  • BHF
  • Associazione Italiana per la Ricerca sul Cancro (27521, IG2022)
  • British Heart Foundation (FS/18/53/33863)
  • University of Cambridge
  • Academy of Medical Sciences

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL). https://app.cochat.ai/papers/10.1016/j.molmet.2023.101728
The paper
Mocciaro, G., Allison, M., Jenkins, B., Azzu, V., Huang-Doran, I., Herrera-Marcos, L. V., Hall, Z., Murgia, A., Susan, D., Frontini, M., Vidal-Puig, A., Koulman, A., Griffin, J. L., & Vacca, M. (2023). Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL). Molecular Metabolism. https://doi.org/10.1016/j.molmet.2023.101728

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.